| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P819 | ADS bibcode | 2016PLoSO..1146803Y |
| P356 | DOI | 10.1371/JOURNAL.PONE.0146803 |
| P8608 | Fatcat ID | release_tghnfyvbzzgbtmfxuiuptcwk6m |
| P932 | PMC publication ID | 4723146 |
| P698 | PubMed publication ID | 26799744 |
| P5875 | ResearchGate publication ID | 291517554 |
| P2093 | author name string | Jian Hu | |
| Ping Yuan | |||
| Wang Lv | |||
| Xiao-Shuai Yuan | |||
| Abudumailamu Abuduwufuer | |||
| Lu-Ming Wang | |||
| Jin-lin Cao | |||
| P2860 | cites work | BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence | Q27853042 |
| TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma | Q27853068 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 | ||
| Telomerase regulation at the crossroads of cell fate | Q28308086 | ||
| TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. | Q54347306 | ||
| Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. | Q54374929 | ||
| Melanomas of unknown primary frequently harbor TERT-promoter mutations | Q87164455 | ||
| Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss | Q39139952 | ||
| TERT promoter mutations contribute to subset prognostication of lower-grade gliomas | Q39150267 | ||
| TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection | Q42216457 | ||
| TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. | Q42456732 | ||
| TERT promoter mutations predict worse survival in laryngeal cancer patients | Q43740263 | ||
| TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas | Q43801346 | ||
| Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study | Q43848797 | ||
| Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. | Q45143637 | ||
| Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. | Q47704838 | ||
| High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression | Q48857394 | ||
| Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. | Q52998892 | ||
| Recurrent TERT promoter mutations in non-small cell lung cancers. | Q54182438 | ||
| TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. | Q54297209 | ||
| TERT promoter mutations in clear cell renal cell carcinoma. | Q54314475 | ||
| TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas | Q28397245 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Telomeres and human disease: ageing, cancer and beyond | Q29615353 | ||
| Regulation of telomerase by telomeric proteins | Q29616133 | ||
| TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer | Q33682388 | ||
| TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas | Q33688439 | ||
| Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas | Q33688915 | ||
| The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors | Q33709979 | ||
| Melanoma genetics and the development of rational therapeutics | Q33726956 | ||
| TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas | Q33769095 | ||
| Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma | Q33917659 | ||
| Alternative lengthening of telomeres: models, mechanisms and implications | Q34107386 | ||
| Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer | Q34150095 | ||
| TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas | Q34313648 | ||
| High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins | Q34469034 | ||
| TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations | Q34499685 | ||
| Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again | Q34527718 | ||
| TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma | Q34654382 | ||
| Oncogenic Braf induces melanocyte senescence and melanoma in mice | Q34974162 | ||
| Telomerase as a promising target for human cancer gene therapy. | Q35126106 | ||
| Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis | Q36107360 | ||
| Human melanocyte biology, toxicology, and pathology | Q36314397 | ||
| Telomere and telomerase in stem cells | Q36758330 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| Role of telomeres and telomerase in genomic instability, senescence and cancer | Q36927502 | ||
| High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions | Q37064910 | ||
| Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. | Q37149600 | ||
| TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism | Q37256055 | ||
| TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma | Q37316068 | ||
| Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. | Q37624069 | ||
| TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine | Q37663771 | ||
| Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia | Q38982558 | ||
| The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas | Q39076273 | ||
| Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome | Q39098321 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0146803 | |
| P577 | publication date | 2016-01-22 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis | |
| P478 | volume | 11 |
| Q92786863 | Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation |
| Q47916891 | Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. |
| Q100526089 | Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations |
| Q52727349 | Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. |
| Q92749153 | Risk Factors for Early Mortality Among Patients with Glioma: A Population-Based Study |
| Q41896400 | Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report |
| Q64935865 | TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q49194424 | The prognostic value of NRF2 in solid tumor patients: a meta-analysis |
| Q49436326 | The prognostic value of p62 in solid tumor patients: a meta-analysis |
| Q51764891 | Trade-offs in aging lung diseases: a review on shared but opposite genetic risk variants in idiopathic pulmonary fibrosis, lung cancer and chronic obstructive pulmonary disease. |
Search more.